Medicalgorithmics S.A. — Regulatory Filings 2026

May 13, 2026

Report Content Conclusion of a letter of intent for the development of a minimallyinvasive robotic system for the treatment of structural heart defects

Current report no.: 18/2026

Date: May 13, 2026

Legal basis: Article 17(1) of the MAR Regulation - confidentialinformation

Management Board of Medicalgorithmics S.A. with its registered office inWarsaw (the "Company") informs that on 13 May 2026, the Company hasentered into a letter of intent (the "Letter of Intent") with theZbigniew Religa Foundation for the Development of Cardiac Surgery("FRK") and the Company's shareholder Biofund Capital Management LLC("BioFund"), (collectively, the "Parties") relating to the plannedcooperation of the Parties in connection with the potentialimplementation of a project involving the design, development andcommercialization of a next-generation minimally invasive robotic systemintended for the treatment of structural heart defects (the "Project").

The Letter of Intent is non-binding, except for the provisions relatingto negotiation exclusivity, confidentiality and public communications,which are binding, and constitutes an expression of the Parties'intention to jointly pursue the Project on the terms set forth therein.In accordance with its provisions, the cooperation is intended toinclude, in particular, activities involving the design, development andpotential commercialization of solutions combining medical imaginganalysis software, robotic systems and elements supporting clinicalworkflows.

The Parties have indicated, inter alia, that in order to implement theProject they intend to carry out further conceptual, technical andorganizational work, including determining the cooperation model (inparticular, the possible establishment of a joint entity), theprinciples for the Parties' contributions (including technology,know-how and funding), as well as the framework for commercialization ofthe Project. The Parties have also outlined general assumptionsregarding intellectual property principles applicable to the Project.The detailed terms of cooperation are to be specified in separate,binding agreements.

The Parties have further agreed to conduct exclusive negotiations withrespect to the Project for a period of 90 days from the date ofexecution of the Letter of Intent. At the same time, the Companyindicates that as of the date of publication of this report no bindingagreements regarding the implementation of the Project have beenconcluded, and the undertaking of further actions, including theexecution of definitive agreements, is subject to the results of ongoinganalyses and negotiations between the Parties and is not certain.

In the opinion of the Management Board, the execution of the Letter ofIntent constitutes a significant event for the Company, as it alignswith the development of the Company's strategic business directions andmay represent an important step towards building therapeuticcapabilities in the field of cardiac surgery, which, if definitiveagreements are concluded and the Project is implemented, may impact thedevelopment of the Company's business operations and its growthprospects.